SFIB vs PENG Block in the Anesthesia for Total Hip Replacement
Launched by STATE BUDGETARY HEALTHCARE INSTITUTION, NATIONAL MEDICAL SURGICAL CENTER N.A. N.I. PIROGOV, MINISTRY OF HEALTH OF RUSSIA · Jul 2, 2025
Trial Information
Current as of July 24, 2025
Enrolling by invitation
Keywords
ClinConnect Summary
Patients will be randomized into three groups group:
Group 1: General anesthesia with SFIB
In this group, under the ultrasound control, a local anesthetic will be injected into the interfacial space of the iliac muscle, in the area of the passage of the deep artery that surrounds the ilium. The block will be performed over the inguinal fold medial to the upper anterior iliac spine. After ultrasound identification of the needle's location in the interfacial space, 40 ml of a 0.5% solution of Ropivacaine will be administered.
Group 2: General anesthesia with PENG block
The block is perfor...
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Signed, dated informed consent form
- • Age from 50 to 75 years
- • Indications for primary total hip replacement
- • American Society of Anesthesiologists (ASA) score from 1 to 3
- Exclusion Criteria:
- • Patients receiving beta blockers;
- • Infectious manifestations at the puncture site;
- • Bleeding, clinically significant hypovolemia of any origin, shock;
- • Disorders of the blood coagulation system;
- • Intolerance to local anesthetics;
- • Demyelinating diseases of the nervous system;
- • Allergy to local anesthetics;
- • Psychiatric diseases;
- • Any conditions that prevent obtaining informed consent.
About State Budgetary Healthcare Institution, National Medical Surgical Center N.A. N.I. Pirogov, Ministry Of Health Of Russia
The National Medical Surgical Center named after N.I. Pirogov, a state budgetary healthcare institution under the Ministry of Health of Russia, is a leading clinical trial sponsor dedicated to advancing medical research and improving patient outcomes. With a strong emphasis on innovative surgical techniques and comprehensive healthcare solutions, the center operates at the forefront of clinical trials, facilitating the development and evaluation of new therapies and medical devices. Leveraging its state-of-the-art facilities and a team of expert clinicians, the institution fosters collaboration with national and international research entities to enhance the efficacy and safety of medical interventions, ultimately contributing to the advancement of public health in Russia and beyond.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Moscow, , Russian Federation
Patients applied
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported